N/A
N=91
Innate Immunity and Respiratory Syncytial Virus (RSV) Infection in Children
Respiratory Syncytial Virus Infection
Bottom Line
View on ClinicalTrials.gov: NCT00593918 ↗Enrolled (actual)
91
Serious AEs
0.0%
Results posted
May 2010
Primary outcome: Primary: Nasal Interferon (IFN)-a2 — 10; 26 pg/ml — p=0.04
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Pediatric
- Sex
- All
- Sponsor
- University of Wisconsin, Madison
- Primary completion
- May 2008
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Nasal Interferon (IFN)-a2 |
10; 26 | 0.04 sig |
| PRIMARY Percentage of Participants With Detected Nasal Interferon (IL)-2 Cytokine Expression |
0; 44 | 0.14 |
Summary
In this project we will study the capacity for single nucleotide polymorphisms (SNP) in TLR4 gene to induce varying levels of inflammatory chemokine and cytokine production.
Eligibility Criteria
Inclusion Criteria
- Parental or sibling history of asthma.
- Child must be less than 24 months of age.
- Presence of viral upper or lower respiratory tract symptoms.
Exclusion Criteria
- History of recurrent wheezing requiring systemic corticosteroids.
- Prior history of lung disease.
- Birth < 36 weeks gestation.
- Immunodeficiency
- Treatment with ribavirin, systemic or inhaled corticosteroids during the RSV infection.
- Congenital heart disease.
- No history of parental or sibling asthma.
- Less than 48 hour or more than 5 day duration of viral URI symptoms since the peak symptoms from RSV would be expected to occur from 2-5 days into course of infection.
Data sourced from ClinicalTrials.gov (NCT00593918). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.